Gilead Sciences, Inc.

As of June 30, 2026, Gilead Sciences, Inc. carries a market capitalization of 156.37B, placing it among publicly traded companies globally. Its enterprise value stands at 179.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Gilead Sciences, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Gilead Sciences, Inc. has 1.24B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.14, and the price-to-book ratio stands at 13.22.

As of June 30, 2026, Gilead Sciences, Inc. trades at an EV/EBITDA multiple of 681.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 179.35B versus a market cap of 156.37B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Gilead Sciences, Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 223.48, indicating elevated leverage, while an interest coverage ratio of 0.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. posted a negative return on equity (ROE) of -20.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.17, reflecting losses generated across the asset base. The company generates approximately 1.78M in revenue per employee across its workforce of 17,150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.29 indicates how many times Gilead Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. recorded 1.29B in income tax expense. The company reported a pretax loss of -1.95B and -3.24B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Gilead Sciences, Inc.'s stock has gained approximately 27.35% over the past 52 weeks. The 50-day moving average sits at 148.43, while the 200-day moving average is 138.66.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. generated 30.46B in revenue and converted that into -3.24B in net income, yielding earnings per share of -2.59. EBITDA reached 263.00M, while operating income came in at 11.72B.

As of June 30, 2026, Gilead Sciences, Inc. holds 3.18B in cash and equivalents against 26.25B in total debt, resulting in a net debt position of 23.07B. Total book value stands at 11.83B, with working capital of 2.93B providing operational flexibility.

Gilead Sciences, Inc. produced 13.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -609.00M in capital expenditures, free cash flow totaled 12.94B - equivalent to 10.42 per share.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. posted a gross margin of 79.59, reflecting its pricing power and cost economics. The operating margin of 38.47 and net profit margin of -10.64 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. paid dividends of 3.27 per share. The dividend payout ratio of -125.56 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.21, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Gilead Sciences, Inc. shareholders.

Gilead Sciences, Inc.'s most recent stock split took place on January 28, 2013 with a 1:2 split ratio.

As of June 30, 2026, Gilead Sciences, Inc. has an Altman Z-Score of 5.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.